Autolus Therapeutics plc ADR [AUTL] stock prices are up 11.28% to $1.48 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AUTL shares have gain 9.63% over the last week, with a monthly amount glided 3.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Autolus Therapeutics plc ADR [NASDAQ: AUTL] stock has seen the most recent analyst activity on November 18, 2024, when Goldman upgraded its rating to a Buy and also boosted its price target to $7.60 from $7. Previously, Redburn Atlantic upgraded its rating to Buy on November 15, 2024, and kept the price target unchanged to $13. On November 09, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $10 on the stock. Bryan Garnier initiated its recommendation with a Buy and recommended $5 as its price target on March 17, 2023. Jefferies upgraded its rating to Buy for this stock on June 14, 2021, and upped its price target to $12. In a note dated January 29, 2021, JP Morgan downgraded an Neutral rating on this stock but restated the target price of $9.
The stock price of Autolus Therapeutics plc ADR [AUTL] has been fluctuating between $1.11 and $5.00 over the past year. Currently, Wall Street analysts expect the stock to reach $8.87 within the next 12 months. Autolus Therapeutics plc ADR [NASDAQ: AUTL] shares were valued at $1.48 at the most recent close of the market. An investor can expect a potential return of 499.32% based on the average AUTL price forecast.
Analyzing the AUTL fundamentals
The Autolus Therapeutics plc ADR [NASDAQ:AUTL] reported sales of 9.01M for trailing twelve months, representing a drop of -10.99%. Gross Profit Margin for this corporation currently stands at -2.72% with Operating Profit Margin at -29.73%, Pretax Profit Margin comes in at -26.01%, and Net Profit Margin reading is -26.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.53 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Autolus Therapeutics plc ADR [NASDAQ:AUTL]’s Current Ratio is 9.21. Also, the Quick Ratio is 8.99, while the Cash Ratio stands at 1.44. Considering the valuation of this stock, the price to sales ratio is 43.72, the price to book ratio is 1.06.
Transactions by insiders
Recent insider trading involved Martin Pule, Officer, that happened on Sep 16 ’24 when 0.7 million shares were purchased.
